-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lymph node metastasis (LNM) found after resection of intrahepatic cholangiocarcinoma (IHC) will greatly reduce the survival rate of patients.
Jolissaint et al.
The prognosis of patients with or without lymph node metastasis using different treatments
The prognosis of patients with or without lymph node metastasis using different treatmentsThe results of the analysis showed that in the absence of lymph node metastasis, the median overall survival of patients with tumors removed by surgery was the longest (OS: 59.
In the absence of lymph node metastasis, patients whose tumors were surgically removed had the longest median overall survival, followed by patients treated with HAIC, and those treated with SYS had the shortest median overall survival.
In the case of lymph node metastasis, there is no significant difference in the survival of patients treated with surgery or HAIC
Prognosis of patients with or without genetic variants
Prognosis of patients with or without genetic variantsCompared with patients without mutations (wild-type), patients with at least one high-risk genetic variant (TP53 mutation, KRAS mutation, CDKN2A/B deletion) positive lymph node metastasis, no matter which treatment is used, the prognosis is poor (medium) Bit OS was 12.
Compared with patients who do not carry the mutation (wild-type), patients with at least one high-risk genetic variant (TP53 mutation, KRAS mutation, CDKN2A/B deletion) positive lymph node metastasis, no matter which treatment is used, the prognosis is poor
Prognosis of patients with or without IDH1/2 mutations
Prognosis of patients with or without IDH1/2 mutationsIn contrast, the survival time of lymph node-positive patients with IDH1/2 mutations is not significantly different from that of wild-type patients.
In summary, for IHC patients with positive lymph node metastasis, there is no difference in survival between surgical resection and hepatic arterial infusion chemotherapy, but both are better than system chemotherapy alone .
For IHC patients with positive lymph node metastasis, there is no difference in survival between surgical resection and hepatic artery infusion chemotherapy, but both are better than system chemotherapy alone.
Original source:
Jolissaint Joshua S, Soares Kevin C, Seier Kenneth P et al.
org/10.
1158/1078-0432.
CCR-21-0412" target="_blank" rel="noopener">Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment -Related Outcomes and the Role of Tumor Genomics in Patient Selection
in this message
